{"entity":{"id":"nct06984588","kind":"trial","name":"A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer","aka":[],"tldr":"A phase 2/3 trial testing Uliledlimab in non-small-cell lung cancer, active and no longer recruiting.","summary":"A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer is a phase 2/3 interventional study registered as NCT06984588, led by TJ Biopharma, and active but no longer recruiting on the registry. Official title: A Phase II/III, Randomised, Multicenter, Open-Label Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer. Planned enrolment is 450 participants (estimated). The study started in 2024-03-28 and primary completion is expected in 2028-08-05. No results have been posted on ClinicalTrials.gov.","status":"active","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT06984588","url":"https://clinicaltrials.gov/study/NCT06984588"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["uliledlimab"],"companies":["tj-biopharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06984588","phase":"2/3","setting":"A Phase II/III, Randomized, Multicenter, Open-Label Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer","sponsor":"TJ Biopharma","started":"2024-03-28","startedType":"actual","enrolled":450,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06984588/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"uliledlimab","kind":"drug","name":"Uliledlimab","route":"/drugs/uliledlimab/"}],"company":[{"id":"tj-biopharma","kind":"company","name":"TJ Biopharma","route":"/companies/tj-biopharma/"}]}}